VDAC1 inhibitor

VDAC1 inhibitors represent a class of research-stage small molecule compounds designed to target the Voltage-Dependent Anion Channel 1 (VDAC1), a mitochondrial outer membrane protein that regulates metabolic flux and the apoptotic pathway. These inhibitors, which include notable research compounds such as VBIT-3 and VBIT-4, primarily work by preventing the oligomerization of VDAC1. This oligomerization is a critical early step in the mitochondrial-mediated apoptotic pathway, as it facilitates the release of cytochrome c into the cytosol. By stabilizing VDAC1 in its monomeric state, these agents can protect against mitochondrial dysfunction, reduce reactive oxygen species (ROS) production, and maintain intracellular calcium homeostasis. Potential therapeutic applications for VDAC1 inhibitors are broad, encompassing neurodegenerative diseases (e.g., Alzheimer's and Parkinson's), cardiovascular conditions, and inflammatory bowel diseases (Crohn's disease and ulcerative colitis). Recent research also indicates that the STAT3-VDAC1 axis is vital for the survival of leukemic stem cells in acute myeloid leukemia (AML), suggesting that VDAC1 inhibition may be a promising strategy for overcoming resistance to standard treatments like venetoclax.

Other names

VDAC1 inhibitorsVDAC-1 inhibitorsVDAC 1 inhibitorsVoltage-dependent anion channel 1 inhibitorsVDAC1 antagonistsVDAC-1 antagonistsVDAC 1 antagonists